Preimplantation Genetic Diagnosis Market| Key Players - Genesis Genetics, Genea Ltd., Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics

Preimplantation genetic diagnosis (PGD) is the inspection of an embryo in vitro in order to eliminate a genetic condition in case a high risk of that condition is known. PGD is an evolving technique that provides a practical alternative to prenatal diagnosis and termination of pregnancy for couples who are at substantial risk of transmitting a serious genetic disorder to their offspring. Growing incidence of infertility across the world is the major driver of the PGD market. Preimplantation genetic diagnosis plays an important role in the detection and determination of genetic disorders, sex-linked diseases, and chromosomal abnormalities in the embryo before IVF can be performed. Rising incidence of infertility coupled with growing awareness about IVF and PGD is the major factor driving the PGD market in Asia.

Get Report Sample Copy @ https://www.mrrse.com/sample/1674

The preimplantation genetic diagnosis (PGD) market in Asia has been segmented based on test type, end-user, and geography. Based on test type, the market has been segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. The market analysis is based on market size and forecast in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) for the period 2015 to 2023, considering 2014 as the base year. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers.

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes Porter’s Five Forces Analysis, overview of PGD, Regulatory Policies and Legality Framework for PGD, Heat Map Analysis for key market players, and country-wise number of PGD Centers in Asia. The report provides a detailed industry analysis of the preimplantation genetic diagnosis (PGD) market in Asia with the help of market attractiveness analysis, by geography, for the year 2014.

The market has been analyzed for Asia covering South Eastern Asia, Eastern Asia, Southern Asia, Central Asia, and Western Asia. The market size and forecast of the regional and country-wise markets is provided for the period 2013 to 2023. CAGR (%) for each region is also estimated for the period 2015 to 2023, considering 2014 as the base year. South Eastern Asia includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Rest of SEA. Eastern Asia comprises China, Japan, South Korea, and Rest of Eastern Asia. Southern Asia constitutes India, Sri Lanka, and Rest of Southern Asia. Western Asia includes Israel, Turkey, Jordan, Saudi Arabia, the United Arab Emirates, and Rest of Western Asia. Eastern Asia accounted for the largest share of the PGD market in Asia.

The report also provides recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the PGD market in Asia. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc.(U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.). The market share analysis of key players involved the study of company products or services portfolio, post sales services and maintenance, sales revenue, and its geographical presence.

The PGD market in Asia has been segmented as follows:

Asia Preimplantation Genetic Diagnosis (PGD) Market, by Test Type
PGD for Aneuploidy Screening
PGD for Chromosomal Aberrations
PGD for Gender Selection
PGD for HLA Typing
PGD for Single Gene Disorder
PGD for X-linked diseases
Asia Preimplantation Genetic Diagnosis (PGD) Market, by End-user
Fertility Clinics
Health Care Facilities (including hospitals, diagnostic centers, and health care facilities)
Academic Institutes and Research Centers
Asia Preimplantation Genetic Diagnosis (PGD) Market, by Geography
South Eastern Asia
Indonesia
Malaysia
Philippines
Singapore
Thailand
Rest of SEA
Eastern Asia
China
Japan
South Korea
Rest of Eastern Asia
Southern Asia
India
Sri Lanka
Rest of Southern Asia
Central Asia
Western Asia
Israel
Turkey
Jordan
Saudi Arabia
United Arab Emirates
Rest of Western Asia

Send an Enquiry @ https://www.mrrse.com/enquiry/1674

Contact Us

State Tower
90, State Street
Suite 700
Albany, NY – 12207(USA)
United States Telephone: +1-518-730-0559
Email: sales@mrrse.com

About Market Research Reports Search Engine (MRRSE)

Market Research Reports Search Engine (MRRSE) is an industry-leading database of Market Research Reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.

MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.

This release was published on openPR.